Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ALX Oncology

Request full access

Clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway and enhance immune system response

South San Francisco, United StatesFounded 2015Biotech & Life Sciences

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company dedicated to developing therapies that help patients combat cancer. The company focuses on blocking the CD47 checkpoint pathway to bridge the innate and adaptive immune systems. Its lead product candidate, evorpacept (ALX148), is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has shown promising clinical responses in both hematologic and solid malignancies when used in combination with leading anti-cancer agents. ALX Oncology operates in the biopharmaceutical market, primarily serving patients with various forms of cancer. The company generates revenue through the development and potential future commercialization of its therapeutic candidates.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020
Employees
63
Open positions
7
Dealroom signal
62.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Investment activity
1 company, latest Oct 2021
Capital deployed
—
Preferred round
ACQUISITION

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Jan 2026 $150M — OrbiMed · Redmile Group · venBio Partners · RA Capital Management ↗
POST IPO EQUITYOther financing Oct 2023 $63M — Lightstone Ventures · Ireland Strategic Investment Fund ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

ALX Oncology website traffic

Latest recorded traffic for ALX Oncology is 4.4K monthly website visits, down 15.4% over the last three months. ALX Oncology's team declined 3.1% over the past year.

Latest monthly visits4.4K 3-month web change-15.4% 1-year team growth-3.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ALX Oncology in the South San Francisco ecosystem

Live from Dealroom

The ALX Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • venBio Partners
  • Lightstone Ventures

Series B and later18 investors entered at this stage

Other known investors1 additional known investor

  • Stanford University
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ALX Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ALX Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.